2020 Press Releases

 Addex Therapeutics

ADDEX ANNOUNCES PRICING OF $10.0 MILLION GLOBAL OFFERING
January 7, 2021

Harpoon Therapeutics logo

HARPOON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
January 6, 2021

Harpoon Therapeutics logo

HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORS
January 4, 2021

PassageBio

HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORS
January 4, 2021

Neurana Pharmaceuticals

Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 Study
December 21, 2020

Kyruus logo

Kyruus and HealthSparq Come Together to Transform Care Navigation Through Novel Payer-Provider Collaboration
December 17, 2020

Arvinas logo

Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
December 14, 2020

Arvinas logo

Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110
December 14, 2020

Kitcheck logo

Kit Check Launches Streamlined Mobile Pharmacy to Boost Efficiency
December 8, 2020

Kyruus logo

Kyruus Named Winner of the Powerhouse Healthcare Company Category at New England Venture Capital Association’s 2020 NEVY Awards
December 8, 2020

Harpoon Therapeutics logo

HARPOON THERAPEUTICS REPORTS CLINICAL PROGRESS ACROSS ALL FOUR TRITAC® PIPELINE DEVELOPMENT PROGRAMS
December 8, 2020

Edgewise

Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program
December 8, 2020

Deciphera logo

Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor
November 30, 2020

Iterum Therapeutics

Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
November 30, 2020

Glympse Bio

First-In-Human Data Supporting the Safety of Glympse Bio’s Biosensors are Presented at the AASLD 2020 Annual Meeting
November 13, 2020

Edgewise

Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular Dystrophy
November 11, 2020

Deciphera logo

Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
November 11, 2020

Deciphera logo

Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
November 11, 2020

TigerConnect

Study: Telehealth Achieves Nearly 90% Customer Satisfaction
October 29, 2020

Aptinyx logo

Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
October 26, 2020

Aptinyx logo

Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder
October 19, 2020

Arvinas logo

Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins
October 14, 2020

TigerConnect

TigerConnect Closes $45M Series D To Meet Soaring Demand
October 8, 2020

Kitcheck logo

Kit Check and Sandoz Collaborate to Launch RFID-tagged Generic Injectables in October 2020
October 1, 2020

Aptinyx logo

Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia
September 28, 2020

Kitcheck logo

Kit Check Extends Partnership with Premier Inc. in Multi-Year Contract to Further Advance Pharmacy Visibility with Diversion Detection Software and Medication Management
September 1, 2020

CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative Disease
September 15, 2020

Kyruus logo

Adventist Health Enhances Online Access for Both New and Existing Patients with Kyruus and Cerner Collaboration 
September 15, 2020

Saniona Press

Saniona successfully raises USD 65 million (approximately SEK 567 million) in a directed issue of shares
September 14, 2020

TigerConnect

TigerConnect Acquires Call Scheduler, Launches Fully-Integrated TigerSchedule™ to Simplify Physician On-Call Scheduling
September 1, 2020

Principia

Sanofi to acquire Principia Biopharma
August 17, 2020

Escape Bio Press

ESCAPE BIO CLOSES $73 MILLION IN CROSSOVER FINANCING TO ADVANCE CLINICAL DEVELOPMENT OF PRECISION NEUROLOGY MEDICINES FOR GENETIC NEURODEGENERATION – ESCAPE BIO
August 10, 2020

ReViral

ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection
August 4, 2020

Pearl Therapeutics

Breztri Aerosphere approved in the US for the maintenance treatment of COPD
July 24, 2020
Glympse Bio
Glympse Bio Announces $46.7 Million Series B Financing
July 15, 2020

TigerConnect

KLAS Rates TigerConnect Among Top Advanced Clinical Communication Platforms
 July 8, 2020

Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
June 30, 2020

Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections
June 29, 2020

Principia

Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
June 23, 2020

Principia

Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
June 23, 2020

Brightinsight logo

BrightInsight Raises $40M in Series B Funding to Cement our Position as the Leading Global Regulated Digital Health Platform for Biopharma and Medtech
June 23, 2020

Aptinyx logo

Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder
June 18, 2020

Kyruus logo

Inspira Health Enables More Streamlined and Seamless Access to Care with Kyruus
June 16, 2020

Principia

Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
June 12, 2020

Principia

Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
June 12, 2020

Kyruus logo

Kyruus Secures $30 Million Investment from Francisco Partners
June 10, 2020

Neurana Pharmaceuticals

Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study
June 8, 2020

Neurana Pharmaceuticals

Neurana Pharmaceuticals Announces Publication of Driving Study
May 13, 2020

Kitcheck logo

Kit Check Announces New Sanitization Feature and Medication Tagging Milestone
May 4, 2020

Rallybio

Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020
May 19, 2020

Deciphera logo

FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
May 15, 2020

Brightinsight logo

BrightInsight and CSL Behring Announce Global Digital Health Partnership to Improve Treatment Experience for Patients with Rare Diseases
May 6, 2020

Harpoon Therapeutics logo

HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN217, A BCMA TARGETING TRITAC, FOR MULTIPLE MYELOMA
April 27, 2020

TigerConnect

TigerConnect Launches TigerTouch Video and Voice Telehealth Features to Help Hospitals Combat COVID-19
April 16, 2020

Brightinsight logo

BrightInsight Named 2019 Google Cloud Technology Partner of the Year for the Healthcare Industry for Second Year in Row
April 6, 2020

Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)
March 31, 2020

Brightinsight logo

BrightInsight Announces Global Digital Health Partnership with AstraZeneca
March 25, 2020

TigerConnect

TigerConnect extends patient communication platform, tools during coronavirus pandemic
March 13, 2020

Deciphera logo

Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
February 19, 2020

Deciphera logo

Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
February 12, 2020

Kitcheck logo

Kit Check’s Bluesight for Controlled Substances™ Named Category Leader for Drug Diversion Monitoring in 2020 Best in KLAS Report
January 31, 2020

Aptinyx logo

Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease
January 30, 2020

TigerConnect

Key customer wins, rapidly growing customer base, and bold product vision accelerate TigerConnect’s role as a force of change for Healthcare collaboration
January 29, 2020

Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors
January 17, 2020

Deciphera logo

Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones
January 13, 2020

Aptinyx logo

Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease
January 10, 2020

Principia

Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases
January 7, 2020